Member Info for Pingu777

Still at it is our resident daft question asker MrIndia. Im pretty sure the (not so) subtle deramper is down to his last avenue of weakness now. Director buys.

Whilst Director buys may have helped the Sp bounce, they're not exactly essential to the success of the company. Just a nice to have. Which leave us with.... no road blocks and a clear path to commercialisation.

HEMO will continue marching onwards with its billion dollar tech! Don't get muddled people. Vlad again referred to clinical proof of concept as being where the value of working drugs skyrockets. End of phase 1/2a trials. Not quite as far away some would have you believe. Eyes on the prize.

Youre spot on. An update is coming on CAR T and HEMO has the funding required to take a billion dollar drug to proof of concept. Nearer the end of the trials if more cash is needed HEMO can go non dilutive as it is such a ground breaking treatment

CDX similarly £5m for trials then at some point near then end they'll need more cash. and HEMO can sort ti with grants, sponsorship and little old Eli who are waiting to swoop.

I agree that is numerically a possibility. But it just doesn't work like that. No one buying such a big wedge would sell off so slowly. They flip as many as poss or hold for a proper rise. They could have sold into the one or two decent runs we've had.

But I think most flippers did their thing in the ensuing days after the raise and then the remainders who were comfortable to hold likely still do so.

IMO

Brewsky agree with all

I just typed a deeper response but lost it! Basically the 250k is nothing. Eli have handed it over to Vlad to privet up at proof of concept. Then he will take it back to them and that is the big money chat. It could be earlier if Eli are keeping tabs on the trial progress.

Ive been told one of Mr Walt's areas of expertise is securing non-dilutive funding ie grants, sponsorship etc. This is an avenue we have been unable to pursue previously. Submitting an IND app will open such doors.

Im pretty confident Eli Lilly will get their wallets out with some supportive funding when the time is right. Not required just yet mind.

Don’t feed them mate!

The SP is currently ridiculous and EXTREMELY frustrating but the companies progress is excellent.

Someone come on here and tell me what HEMO haven’t done well with the science and the link with Eli Lilly on multiple fronts and I’ll happily debate it. Any chinks or flaws with the commercial prospects? Fire away.

You’d think it might be a takeover target but it doesn’t seem to work like that in pharma. Not usually much hostility between big/junior pharmas working together.

And Eli for me in particular aren’t about that. They’re happy to get the cheque book out and write big numbers providing you can prove it works.

Proof of concept end of phase1/2a trials. Some time around then or in the run up as trial results are monitored I think they’ll be sniffing about.

I remain ultra confident of success at HEMO. The SP is frustrating but will catch up to the intrinsic value at some point. Let’s have a good run into the year end!

Don’t get scared into giving up your shares people.

Agreed dhub

MrIndia is a deramper

It still amazes me people take him seriously and talk to him!

Underwhelming SP action. Although I expect us to rise over the coming days.

The news is outstanding and validates the quality of HEMOs work. Eli letting us prove it works now before they’ll buy it! Makes sense.

Other projects can be driven forward now the CDX IP deal is done. Predicting a strong Q4 of news and SP positivity.

The awaited RNS should be extremely positive for HEMO. A proper MCAP will be found once the masses realise HEMO have continued to move things along well with GlobalCo and that they still want CDX all ever since the CLN/no option debacle. Such a bloody mess.

Loads of news flow to come.

We’ve had pre news spikes before on the hype and excitement. Zero excitement this time. The market wants to see the news before it reacts.

Hit us with a GlobalCo deal and then we could see things motor a bit.

It’s not if, but when.

Pre clinical junior pharmas generally don’t work on turnover and P/E ratios incredibly. Have a guess why?

You keep hanging on Stu

You’ll get the SP that comes with the news you desire

Haddy I don’t think you understand how well positioned HEMO are. Simple as that. The SP acts irrespective of anything currently. The interim update was fantastic. Imo of course. Not everyone sees that including you it seems.

The hate and doubt in HEMOs credentials is still strong and explains the struggling SP.

The next few updates hopefully begin to rebuild some trust and prove things have been moving along through the Summer.

Ruthless Stu!

For info I was in receipt of the placing circular when they raised to clear the CLNs. It indicated acquiring GlobalCos IP on CDX would bring little or no up front cost.

FYI.

Sorry so just to conclude

I’ve no idea what impact a CDX deal will have on the SP. But my bets are on it going up though.

My point is my view is there’s a lot more going on that just agreeing the price of the IP with these negotiations.